title: Late renal sequelae in intravenously treated complicated urinary tract infection.
abstract: BACKGROUND
  The treatment of complicated urinary tract infection in children is still a matter of debate. In our hospital, antimicrobial treatment is initiated intravenously, and the duration of this treatment is adapted according to the results of a Tc-99m dimercaptosuccinic acid (DMSA) scintigraphy.
  
  
  OBJECTIVE
  This study was conducted to evaluate retrospectively the frequency and the importance of late renal sequelae when treating intravenously for 7 days those patients with an abnormal acute DMSA.
  
  
  METHODS
  A review was conducted of the medical charts of all patients consecutively admitted between 2005 and 2008 with positive urine culture and clinical and biological evidence of complicated urinary tract infection (UTI).
  
  
  RESULTS
  There were 144 patients (59 %) with abnormal early DMSA scintigraphy and 98 (41 %) with normal scintigraphy. The median duration of intravenous treatment was 7.0 days in the children with DMSA lesions and 5.0 days in those without lesions. Obvious renal sequelae were observed on late DMSA scintigraphy in 4 (6 %) out of the 65 patients with an abnormal early DMSA who came back for control scintigraphy.
  
  
  CONCLUSIONS
  Sequelae of acute DMSA lesions observed during complicated UTI treated 7 days intravenously were infrequent. Whether the mode and duration of antimicrobial treatment might explain the low rate of sequelae remains to be demonstrated.
authors.affiliation: Department of Pediatrics, Hospital Saint- Pierre, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Christine
authors.initials: C
authors.lastname: Ferreiro
authors.forename: Amy
authors.initials: A
authors.lastname: Piepsz
authors.forename: Cécile
authors.initials: C
authors.lastname: Nogarède
authors.forename: Marianne
authors.initials: M
authors.lastname: Tondeur
authors.forename: Marc
authors.initials: M
authors.lastname: Hainaut
authors.forename: Jack
authors.initials: J
authors.lastname: Levy
mesh_terms: D000208:Acute Disease; D061605:Administration, Intravenous; D000293:Adolescent; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D010406:Penicillins / Q000627:therapeutic use; D011704:Pyelonephritis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D010406:Penicillins; D019275:Radiopharmaceuticals; C031367:temocillin; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D000667:Ampicillin; D002439:Cefotaxime